The rising prevalence of urticaria is fueling market growth, with increased allergic responses and lifestyle shifts playing key roles. Advances in biologic treatments and a strong development pipeline ...
Compass Pathways' latest update reveals extended trial timelines, staff cuts, and financial concerns, raising questions about ...
Shuttle Pharmaceuticals (NASDAQ: SHPH), a rising force in cancer treatment innovation, has experienced a notable boost in its ...
Anavex Life Sciences' (AVXL) stock surged on new Alzheimer's trial data, but data's inconsistency raises concerns, making the ...
Journey Medical (NASDAQ:DERM) shares are trading higher Monday after the company announced the U.S. Food and Drug ...
Europe has been falling behind on clinical trials over the past decade as pharmaceutical companies shift their focus to the ...
CASGEVY approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treat ...
Real-time index price for S&P 500 Consumer Staples [Sector] (SRCS), along with buy or sell indicators, analysis, charts, ...
Thetis Pharmaceuticals Announces Positive Initial Results From a Phase 1a Study of TP-317, a BLT1 Agonist, in Healthy Subjects.
Nov. 4, 2024 /PRNewswire/ -- Movano Health (NASDAQ: MOVE) announced today that it has submitted a complete response package to the FDA as part of the final phase of the ... in remote patient ...
Lonza’s innovative continuous flow technology and mini-monoplant approach are transforming early-phase drug development. How ...